#1 Clinical Trials Search in Europe

Docetaxel

Docetaxel, also known by its brand name Taxotere, is a chemotherapy drug being studied in various clinical trials for the treatment of different types of cancer. These trials aim to evaluate its effectiveness, safety, and potential combinations with other drugs to improve outcomes for patients with advanced solid tumors, breast cancer, and other malignancies.

Table of Contents

What is Docetaxel?

Docetaxel is a powerful chemotherapy drug used to treat various types of cancer. It’s also known by its brand name Taxotere[1]. Docetaxel belongs to a class of drugs called taxanes, which are derived from yew trees and work by interfering with cell division[2].

What Conditions Does Docetaxel Treat?

Docetaxel is used to treat several types of cancer, including:

  • Breast cancer: It’s used in both early-stage and advanced breast cancer[3]
  • Non-small cell lung cancer: Docetaxel is used as a second-line treatment for this type of lung cancer[1]
  • Prostate cancer: It’s used in combination with other treatments for high-risk localized prostate cancer[4]
  • Gastric (stomach) cancer: Docetaxel is used in combination with other drugs for advanced gastric cancer[5]
  • Head and neck cancers: It’s being studied for use in nasopharyngeal carcinoma, a type of head and neck cancer[6]
  • Germ cell cancers: Docetaxel is being investigated for use in recurrent or refractory germ cell cancers[7]

How Does Docetaxel Work?

Docetaxel works by interfering with the way cancer cells divide and grow. Specifically, it:

  • Stops cancer cells from dividing, which prevents them from growing or causes them to die[7]
  • May also affect the blood vessels that feed tumors, potentially slowing their growth[5]

How is Docetaxel Administered?

Docetaxel is typically given as an intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein. The specific administration details can vary depending on the type of cancer and treatment plan, but generally:

  • It’s often given once every 3 weeks, in what’s called a treatment cycle[6]
  • The infusion usually takes about 1 hour[8]
  • The dose is typically calculated based on your body surface area (which takes into account your height and weight)[9]

Potential Side Effects

Like all chemotherapy drugs, docetaxel can cause side effects. Some common side effects may include:

  • Lowered blood cell counts, which can increase risk of infection or bleeding
  • Nausea and vomiting
  • Hair loss
  • Fatigue
  • Diarrhea
  • Mouth sores

Your healthcare team will monitor you closely for these and other side effects and can provide treatments to help manage them[10].

Ongoing Research and Clinical Trials

Researchers continue to study docetaxel to find new ways to use it effectively. Some areas of ongoing research include:

  • Combining docetaxel with newer immunotherapy drugs for prostate cancer[10]
  • Using docetaxel before surgery (neoadjuvant therapy) in breast cancer to shrink tumors[3]
  • Combining docetaxel with other chemotherapy drugs for gastric cancer[9]
  • Testing docetaxel as part of treatment regimens for nasopharyngeal carcinoma[6]

These studies aim to improve the effectiveness of docetaxel and find new ways to use it to help more patients with cancer.

Aspect Details
Drug Name Docetaxel (Taxotere)
Cancer Types Studied Advanced breast cancer, gastric cancer, non-small cell lung cancer, solid tumors
Administration Method Intravenous (IV) infusion
Common Dosage 75-100 mg/m² every 3 weeks (may vary by trial)
Combination Therapies Capecitabine, Cisplatin, Herceptin (Trastuzumab)
Primary Outcomes Measured Tumor response rate, progression-free survival, overall survival
Secondary Outcomes Safety profile, quality of life, pharmacokinetics
Biomarker Studies Gene expression profiling to predict treatment response

FAQ

  • What is Docetaxel and how does it work? Docetaxel is a chemotherapy drug that belongs to the taxane family. It works by interfering with cell division, which helps to stop cancer cells from growing and spreading.
  • What types of cancer is Docetaxel being studied for? Docetaxel is being investigated for various types of cancer, including advanced breast cancer, gastric cancer, non-small cell lung cancer, and other solid tumors.
  • How is Docetaxel administered in clinical trials? In most trials, Docetaxel is given as an intravenous (IV) infusion, typically every 3 weeks. The dose may vary depending on the specific trial and patient characteristics.
  • Are there any side effects associated with Docetaxel? Common side effects of Docetaxel may include low blood cell counts, fatigue, hair loss, and nausea. Clinical trials closely monitor patients for adverse events and adjust treatment as needed.
  • How do researchers determine if Docetaxel is effective in clinical trials? Researchers assess the effectiveness of Docetaxel by measuring outcomes such as tumor response rate, progression-free survival, and overall survival. They also compare its performance to other treatments or combinations.

Ongoing Clinical Trials on Docetaxel

  • Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

    Recruiting

    3 1 1 1
    Investigated drugs:
    France Germany Italy Portugal Spain

  • Study of ifinatamab deruxtecan alone or in combination with other treatments for patients with metastatic castration-resistant prostate cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Ireland Italy The Netherlands Poland +1

  • Comparing Two Treatment Lengths of Cetuximab, Avelumab, Cisplatin, and Docetaxel for Patients with Returning Spread Head and Neck Cancer

    Recruiting

    2 1 1 1
    Investigated drugs:
    Germany

  • A Study Comparing PF-08046054 to Docetaxel in Adults with Previously Treated PD-L1 Positive Non-Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark Finland France +8

  • Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy The Netherlands Spain

  • Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Hungary Poland Portugal Romania Spain

  • Study of visugromab and nivolumab with or without docetaxel as second-line treatment for patients with metastatic non-squamous non-small cell lung cancer

    Recruiting

    2 1 1
    Investigated drugs:
    Germany Italy Poland Romania Spain

  • A study of sacituzumab tirumotecan versus docetaxel, paclitaxel, or vinflunine for patients with pretreated advanced or metastatic bladder cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Greece Italy The Netherlands +2

  • A study of mRNA-4157 and a drug combination for patients with stage IV non-small cell lung cancer

    Recruiting

    2 1 1
    Investigated drugs:
    France Italy Poland Spain

  • A study of JNJ-78278343 and docetaxel compared to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium France Germany Italy Spain

Glossary

  • Docetaxel: A chemotherapy drug belonging to the taxane family, used to treat various types of cancer by interfering with cell division.
  • Taxotere: The brand name for Docetaxel.
  • Intravenous (IV) infusion: A method of administering medication directly into a vein using a needle or catheter.
  • Neoadjuvant therapy: Treatment given before the main treatment, often used to shrink tumors before surgery.
  • Adjuvant therapy: Additional treatment given after the primary treatment to lower the risk of cancer returning.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives without the cancer progressing.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Adverse events: Undesirable experiences associated with the use of a medical product in a patient.
  • Biomarkers: Measurable indicators of a biological state or condition, often used to predict treatment response or disease progression.

References

  1. https://clinicaltrials.gov/study/NCT00065182
  2. https://clinicaltrials.gov/study/NCT00002662
  3. https://clinicaltrials.gov/study/NCT00206505
  4. https://clinicaltrials.gov/study/NCT01530295
  5. https://clinicaltrials.gov/study/NCT02007148
  6. https://clinicaltrials.gov/study/NCT00916097
  7. https://clinicaltrials.gov/study/NCT00002903
  8. https://clinicaltrials.gov/study/NCT02339532
  9. https://clinicaltrials.gov/study/NCT00816543
  10. https://clinicaltrials.gov/study/NCT03879122